Growth Factor Or Derivative Affecting Or Utilizing Patents (Class 514/7.6)
  • Patent number: 10363223
    Abstract: An encapsulation of deer velvet powder for ensuring delivery of the deer velvet powder to the terminal ileum of the small intestine, thereby ensuring micellization of unaltered molecules of the deer velvet powder, and systemic delivery of the unaltered molecules to all the organs of the body for regeneration and repair. The encapsulation includes: a delayed release capsule, and deer velvet powder contained within the delayed release capsule. The delayed release capsule is acid resistant, thereby protecting the deer velvet powder from digestive processes while transiting the stomach and upper small intestine, enabling the deer velvet powder to be released substantially along the terminal ilium of the small intestine so as to ensure micellization and absorption of unaltered molecules of deer velvet. Thus, swallowing the deer velvet powder encapsulated in a delayed release capsule delivers more of the benefits of deer velvet than standard encapsulations of deer velvet.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: July 30, 2019
    Inventor: William R. Deagle
  • Patent number: 10287246
    Abstract: The present invention relates to methods, formulations, and compositions for the treatment of biofilms. In particular, the application discloses isothiocyanate functional surfactants either alone or combination with adjunct agents to treat biofilms.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: May 14, 2019
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10273205
    Abstract: The present invention relates to methods, formulations, and compositions for the treatment of biofilms. In particular, the application discloses isothiocyanate functional surfactants either alone or combination with adjunct agents to treat biofilms.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: April 30, 2019
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10219996
    Abstract: The invention provides a composition suitable for topical skin application comprising isolated queen bee venom. The queen bee venom has been found to be significantly superior for treating skin conditions relative to the normal bee venom. Therefore the invention also provides a method of treatment or prevention of a skin condition, comprising the topical application of the composition onto the skin of a subject afflicted with the skin condition, or at risk of being afflicted with the skin condition. The skin condition could be skin ageing, elastosis, laxity (sagging), rhytids (wrinkles), skin infection, skin damage, skin burn, pain, and muscle tightness, or combinations thereof.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: March 5, 2019
    Inventor: Deborah Mitchell
  • Patent number: 10206886
    Abstract: The present invention refers to lipid nanoparticles comprising a growth factor and/or an antimicrobial peptide and to the method for their preparation. Moreover, it refers to pharmaceutical compositions comprising such lipid nanoparticles, and a pharmaceutical acceptable carrier. Finally, it also refers to said pharmaceutical composition for its use as medicament and for its use in promoting wound healing, particularly by topical administration.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: February 19, 2019
    Inventors: Eusebio Gainza Lafuente, Garazi Gainza Lucea, Silvia Villullas Rincón, Marta Pastor Navarro, Oihane Ibarrola Moreno, Gorka Alonso Hornes, Angel Del Pozo Pérez, Rosa María Hernández Martín, Manuela Igartua Olaechea, José Luis Pedraz Muñoz
  • Patent number: 10106592
    Abstract: The present invention relates to interleukin-4 receptor-binding fusion proteins. More specifically, the invention provides, in part, fusion proteins that include an interleukin-4 or interleukin-13 protein moiety joined to an anti-apoptotic Bcl-2 family member protein moiety.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: October 23, 2018
    Assignee: Medicenna Therapeutics Inc.
    Inventor: Fahar Merchant
  • Patent number: 9913811
    Abstract: A compound suitable for treating EGFR-dependent non-small cell lung cancer exceptionally inhibits activity of the EGFR kinase, in particular in EGFR-dependent non-small cell lung cancer with intrinsic or acquired resistance against at least one EGFR inhibitor. Methods for inhibiting EGFR kinase activity in non-small cell lung cancer cells which harbor an abnormality in the EGFR gene and for targeting cancer cells harboring an abnormality in EGFR gene by contacting EGFR-dependent non-small cell lung cancer cells with said compound are also provided. The compounds allow for an advantageous inhibition of the EGFR kinase activity and induction of apoptosis of the non-small cell lung cancer cells with abnormality in the EGFR gene. Hence, said compounds represent a highly promising treatment option for patients harboring EGFR-dependent cancer.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: March 13, 2018
    Assignee: Macau University of Science and Technology
    Inventors: Liang Liu, Lai Han Leung, Xia Li, Xing-Xing Fan
  • Patent number: 9839675
    Abstract: Stabilized pharmaceutical formulations of insulin analogs and/or insulin derivatives are disclosed.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: December 12, 2017
    Assignee: SANOFI
    Inventors: Oliver Bley, Petra Loos, Bernd Bidlingmaier, Walter Kamm, Harald Berchtold
  • Patent number: 9717778
    Abstract: The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor I (IGF-I). The method comprises administration of a growth hormone (GH) variant having antagonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (GHR) to a subject in need.
    Type: Grant
    Filed: February 4, 2013
    Date of Patent: August 1, 2017
    Assignee: Antisense Therapeutics Ltd.
    Inventor: George Tachas
  • Patent number: 9700597
    Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: July 11, 2017
    Inventors: Huntington Potter, Timothy Boyd, Heather Sevey Lawrence Jim
  • Patent number: 9629896
    Abstract: The invention relates to a HIP/PAP protein or to one of the derivatives thereof for use thereof for treating or preventing insulin resistance in non-insulin dependent subjects.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: April 25, 2017
    Inventors: Fabrizio Andreelli, Paul Amouyal, Christophe Magnan, Celine Cruciani-Guglielmacci, Jamila Vaivre, Marion Darnaud, Laure Jamot, Christian Brechot, Gilles Amouyal
  • Patent number: 9624268
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease are described.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: April 18, 2017
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Gregory Thomas Bourne, Ashok Bhandari, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Patent number: 9605048
    Abstract: The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD 146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD 146, herein described, may be used to mobilize, in vivo or ex vivo, both mature and immature endothelial cells, as well as to increase their influence on angiogenesis. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: March 28, 2017
    Inventors: Marcel Blot-Chabaud, Karim Harhouri, Nathalie Bardin, Benjamin Guillet, Françoise Dignat-George
  • Patent number: 9545370
    Abstract: A method for preparing a bioactive composition containing conditioned cell culture medium is disclosed. The method comprises culturing cells of two or more eukaryotic cell line to form conditioned culture media, separating the cultured cells from the conditioned culture media, and combining conditioned culture media to form a bioactive composition. Novel bioactive compositions, formulations and their use in treating of a variety of diseases and health conditions are also disclosed.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: January 17, 2017
    Inventor: Greg Maguire
  • Patent number: 9403872
    Abstract: The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: August 2, 2016
    Inventors: Stephen H. Leppla, Shi-Hui Liu, Sarah Netzel-Arnett, Henning Birkedal-Hansen, Thomas Bugge
  • Patent number: 9200040
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: December 1, 2015
    Assignee: Amgen Inc.
    Inventors: Jonathan Daniel Oliner, Hosung Min
  • Patent number: 9155697
    Abstract: Provided is a liquid composition for treating stomatitis, the liquid composition including: an epidermal growth factor; an adhesive polymer; and at least one stabilizer selected from the group consisting of ethylenediaminetetraacetic acid (EDTA) and salts thereof, histidine, lysine and inorganic acid salts thereof, arginin and inorganic acid salts thereof, and dextran. The liquid composition includes a stabilizer selected from EDTA (or salts thereof) and a certain amino acid (or inorganic acid salts thereof) and thus, physicochemical and biological stability of the epidermal growth factor can be substantially increased. Thus, the liquid composition can be stored and distributed for a long period of time. The stabilized composition includes an adhesive polymer, and thus, when ejected in a spray form in the mouth of a user, the liquid composition can be quickly attached to an inflammation site and exhibits effectiveness for a long period of time.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: October 13, 2015
    Assignee: DAEWOONG CO., LTD.
    Inventors: Sun-Hee Kim, Sang-Kil Lee, Chae-Ha Yoon, Sun-Mee Yang, Sang-Hyun Nam, Kyeong-Sun Shin, Seung-Kook Park, Sang-Wook Lee
  • Publication number: 20150147404
    Abstract: LEDGF peptides with anti-protein aggregation activity and methods of use are provided. The LEDGF peptides disclosed herein demonstrate an ability to treat degenerative diseases and diseases with various cellular stresses including oxidative stress and protein-aggregation stress. In addition, extended release formulations, including formulations suitable for ophthalmic administration are provided.
    Type: Application
    Filed: May 21, 2013
    Publication date: May 28, 2015
    Applicant: The Regents of the University of Colorado, a body corporate
    Inventors: Uday B. Kompella, Rinku Baid, Arun K. Upadhyay, Sarath Yandrapu
  • Publication number: 20150140046
    Abstract: Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.
    Type: Application
    Filed: April 12, 2013
    Publication date: May 21, 2015
    Inventors: Antonio Vicente Ferrer Montiel, Gregorio Fernández Ballester, José María García Antón, Cristina Carreño Serraïma, Núria Almiñana Doménech, Raquel Delgado González
  • Publication number: 20150140034
    Abstract: The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals.
    Type: Application
    Filed: September 19, 2014
    Publication date: May 21, 2015
    Inventors: Paul Joseph Dominowski, Dennis L. Foss, Guillermo Gallo, John Morgan Hardham, Richard Lee Krebs, Sandra Ann Marie Lightle, Suman Mahan, Sangita Mediratta, Kaori Mohr, Duncan Mwangi, Sharath K. Rai, Sarah A. Salmon, Shaunak Vora, Lauren Wilmes
  • Publication number: 20150141332
    Abstract: Methods for managing osteoarthritis, in a human or other mammalian subject, comprising the measurement of certain cytokines and growth factors in a tissue sample of a subject, including one or more of platelet-derived growth factor AB (PDGF-AB), platelet-derived growth factor BB (PDGF-BB), and epidermal growth factor (EGF). Tissue samples may be whole blood, blood fractions, urine, saliva, and synovial fluid. Methods include diagnosing osteoarthritis, and methods for assessing the severity of osteoarthritis, such as in subject that have been diagnosed with osteoarthritis using radiographic or other methods. Methods may also include comparison of measured cytokine levels to a reference level. Methods of managing the clinical progression of osteoarthritis include initiating a clinical action based on the difference between the measured cytokine level and a reference level.
    Type: Application
    Filed: June 4, 2013
    Publication date: May 21, 2015
    Applicant: Biomet Biologics, LLC
    Inventor: Krista Toler
  • Publication number: 20150139944
    Abstract: Provided is a separatome-based recombinant peptide, polypeptide, and protein expression and purification platform based on the juxtaposition of the binding properties of host cell genomic peptides, polypeptides, and proteins with the characteristics and location of the corresponding genes on the host cell chromosome, such as that of E. coli, yeast, Bacillus subtilis or other prokaryotes, insect cells, mammalian cells, etc. This platform quantitatively describes and identifies priority deletions, modifications, or inhibitions of certain gene products to increase chromatographic separation efficiency, defined as an increase in column capacity, column selectivity, or both, with emphasis on the former. Moreover, the platform provides a computerized knowledge tool that, given separatome data and a target recombinant peptide, polypeptide, or protein, intuitively suggests strategies leading to efficient product purification.
    Type: Application
    Filed: October 23, 2014
    Publication date: May 21, 2015
    Inventors: Ellen M. Brune, Robert R. Beitle, Mohammad M. Ataai, Patrick R. Bartlow, Ralph L. Henry
  • Publication number: 20150133377
    Abstract: The application of a highly controlled, micron-sized, branched, porous architecture to enhance the handling properties and degradation rate of hydrogels is described in the instant invention. A previously described pattern created through one-step nucleated crystallization in a hydrogel film creates tunable mechanical properties and/or chemical stability for use in tissue engineering applications. The bulk mechanical properties and the degradation rate of the material can be tuned easily by the addition or subtraction of crystalline structure or by the addition and subtraction of backfill material, making this useful for a variety of applications. Relevant mechanical properties that can be tuned through the application of this unique porosity are moduli, elasticity, tensile strength, and compression strength. The method of the present invention can be applied to biopolymers and natural materials as well as synthetic materials.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 14, 2015
    Inventors: Sarah Mayes, Christine Schmidt
  • Publication number: 20150133376
    Abstract: A method for evaluation of cancer diagnosis following cancer radiotherapy, comprising: providing a serum sample of a cancer patient prior to the cancer radiotherapy; and measuring a leukemia inhibitory factor concentration in the serum sample. Also provided is a method for potentiation of cancer radiotherapy, comprising: administrating a leukemia inhibitory factor inhibitor or a leukemia inhibitory factor receptor inhibitor to a subject in need of the cancer radiotherapy.
    Type: Application
    Filed: April 11, 2014
    Publication date: May 14, 2015
    Inventors: Yu-Sun Chang, Shu-Chen Liu, Ngan-Ming Tsang
  • Publication number: 20150133375
    Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 14, 2015
    Inventors: Soren Mogelsvang, Cohava Gelber
  • Publication number: 20150132355
    Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 14, 2015
    Inventors: William D. Carlson, Peter C. Keck, Michael Sworin, Dattatreyamurty Bosukonda
  • Publication number: 20150119326
    Abstract: Methods are presented for the therapeutic administration of angiocidin in the treatment of cancers such as glioma, breast cancer, and leukemia. Methods are also presented for inducing growth arrest and/or apoptosis of tumor cells, as well as inducing differentiation of tumor cells to inhibit tumorigenicity and to confer a non-tumor or healthy phenotype.
    Type: Application
    Filed: October 24, 2014
    Publication date: April 30, 2015
  • Publication number: 20150119324
    Abstract: Provided are methods of delivering at least one pharmaceutical agent to the central nervous system (CNS) of a subject, methods of treating a neurological disorder or pain in a subject that include administering at least one pharmaceutical agent onto a SEM graft in the skull base of the subject. Also provided are methods of treating a neurological disorder or pain in a subject that include forming a SEM graft in the skull base of the subject and administering at least one pharmaceutical agent onto the SEM graft in the skull base of the subject. Also provided are methods of forming a SEM graft in the skull base of a subject, compositions for administration onto a SEM graft in the skull base or into an endonasal reservoir or endonasal reservoir device in a subject, and devices for administering such compositions onto a SEM graft in the skull base of a subject.
    Type: Application
    Filed: January 5, 2015
    Publication date: April 30, 2015
    Inventor: Benjamin S. Bleier
  • Publication number: 20150104484
    Abstract: The present disclosure is directed to articles comprising a polyelectrolyte complex which stores mechanical strain and methods of forming articles comprising a polyelectrolyte complex which stores mechanical strain.
    Type: Application
    Filed: September 22, 2014
    Publication date: April 16, 2015
    Inventors: Joseph B. Schlenoff, Qifeng Wang
  • Patent number: 9006170
    Abstract: The present invention describes therapeutic compositions comprising one or more minerals, including trivalent iron, divalent manganese and salts thereof, suitable in facilitating synthesis and deposition of connective tissue matrix, particularly rich of elastin and collagen, and mitogenic potential in human dermal fibroblasts. It also describes the phenomenon in which stimulation of elastogenesis by arterial SMC associates with a net decrease in proliferation of these cell types. The present invention also describes methods of treatment of human skin fibroblasts and arterial smooth muscle cells. The therapeutic compositions of the present invention comprise one or more of trivalent iron or divalent manganese or salts thereof and may be combined with an elastic tissue digest.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: April 14, 2015
    Assignees: Human Matrix Sciences, LLC, The Hospital for Sick Children
    Inventors: Thomas Mitts, Felipe Jimenez, Aleksander Hinek, Severa Bunda
  • Patent number: 9005648
    Abstract: In alternative embodiments, the invention provides articles of manufacture comprising biocompatible nanostructures comprising PolyEther EtherKetone (PEEK) surface-modified (surface-nanopatterned) to exhibit nanostructured surfaces that promote osseointegration and bone-bonding for, e.g., joint (e.g., knee, hip and shoulder) replacements, bone or tooth reconstruction and/or implants, including their use in making and using artificial tissues and organs, and related, diagnostic, screening, research and development and therapeutic uses, e.g., as primary or ancillary drug delivery devices. In alternative embodiments, the invention provides biocompatible nanostructures that promote osseointegration and bone-bonding for enhanced cell and bone growth and e.g., for in vitro and in vivo testing, restorative and reconstruction procedures, implants and therapeutics.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: April 14, 2015
    Assignee: The Regents of the University of California
    Inventors: Sungho Jin, Garrett Smith, Chulmin Choi
  • Publication number: 20150099012
    Abstract: The present invention relates to a method for increasing retrovirus transcription in an infected eukaryotic cell, comprising increasing Wnt pathway signaling in said cell such that transcription of said retrovirus is increased. Also, the present invention relates to a method of treating a subject infected with a retrovirus, said method comprising administering to said subject an activator of the Wnt pathway in an amount that increased Wnt pathway signaling in resting memory CD4+ T cells of said subject such that the retroviral long terminal repeat (LTR) in said cells is activated or de-repressed.
    Type: Application
    Filed: March 1, 2013
    Publication date: April 9, 2015
    Inventor: Tokameh Mahmoudi
  • Patent number: 8999670
    Abstract: A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: April 7, 2015
    Assignee: OPKO Biologics Ltd.
    Inventors: Fuad Fares, Udi Eyal Fima
  • Patent number: 8993519
    Abstract: Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and neutropenia. The compositions and methods include recombinant human albumin-human granulocyte colony stimulating factor. Pharmaceutical formulations including the recombinant fusion protein, and methods of making such formulations are also described.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: March 31, 2015
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Jason Benjamin Bock, Xia Luo
  • Publication number: 20150086605
    Abstract: The technology described herein is directed to compositions comprising at least a first porous biomaterial layer and a second impermeable biomaterial layer and methods relating thereto. In some embodiments, the compositions and methods described herein relate to wound healing, e.g. repair of wounds and/or tissue defects.
    Type: Application
    Filed: February 5, 2013
    Publication date: March 26, 2015
    Inventors: Joshua R. Mauney, Carlos R. Estrada, David L. Kaplan, Eun Seok Gil
  • Patent number: 8986696
    Abstract: The present invention relates to trans-capsularly administering into a diseased joint an inhibitor of p38 MAP kinase or a different therapeutic agent.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: March 24, 2015
    Assignee: DePuy Mitek, Inc.
    Inventors: Laura J. Brown, Jeffery C. Geesin, Carrie H. Fang, John J. Siekierka
  • Publication number: 20150080301
    Abstract: Disclosed are novel bioabsorbable and biodegradable monomer compounds, bioabsorbable and biodegradable polymers therefrom, and methods of making such monomers and polymers, which are useful in pharmaceutical delivery systems, tissue engineering applications, tissue adhesives products, implantable medical devices, foams and reticulated foams for wound healing and drug delivery, bone hemostats and bone void fillers, adhesion prevention barriers, meshes, filters, stents, medical device coatings, pharmaceutical drug formulations, consumer product and cosmetic and pharmaceutical packaging, apparel, infusion devices, blood collection tubes and devices, other medical tubes, skin care products, and transdermal drug delivery materials.
    Type: Application
    Filed: November 20, 2014
    Publication date: March 19, 2015
    Inventor: Rao S. Bezwada
  • Publication number: 20150072931
    Abstract: The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-?B activity. The modulators may be used, for example, in the treatment of NF-?B-mediated diseases, conditions, and injuries.
    Type: Application
    Filed: June 16, 2014
    Publication date: March 12, 2015
    Inventor: Andrei V. Gudkov
  • Publication number: 20150057221
    Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L1 represented by formula (I): wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R1, R1a, R2, R2a, R3, R3a, X, X1, X2, X3 have the meaning as indicated in the description and the claims and wherein L1 is substituted with one to four groups L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L2 is a single chemical bond or a spacer; and Z is a carrier group. The invention also relates to A-L, wherein A is a leaving group, pharmaceutical composition comprising said prodrugs and their use as medicaments.
    Type: Application
    Filed: October 30, 2014
    Publication date: February 26, 2015
    Inventors: Felix Cleemann, Ulrich Hersel, Silvia Kaden, Harald Rau, Thomas Wegge
  • Publication number: 20150050331
    Abstract: The present invention is directed to a method of making a stable composition comprising growth factors, which may include platelet derived growth factors and transforming growth factors. The method comprises providing human umbilical cord blood plasma containing platelets, but substantially free of whole blood cells, and lysing the platelets to extrude growth factors into the plasma. The plasma may be obtained from multiple donors and pooled to form a homologous plasma mixture. In another embodiment, the growth factors are encapsulated in a liposome formed by a lipid bilayer, wherein the resulting composition remains stable and viable for at least 30 months. The present invention is also directed to the composition produced by the methods of the present invention and the process of applying the composition to a skin defect or wound.
    Type: Application
    Filed: October 29, 2014
    Publication date: February 19, 2015
  • Publication number: 20150044139
    Abstract: The present application relates to use of a Midkine family protein for growing hair on a mammal, or in the manufacture of a medicament for growing hair on a mammal, especially for treatment or prevention of different forms of alopecia.
    Type: Application
    Filed: August 20, 2014
    Publication date: February 12, 2015
    Inventors: Sadatoshi Sakuma, Maria Halasz, Darren Jones
  • Publication number: 20150038403
    Abstract: The present invention provides mimetics of erythropoietin that bind to the erythropoietin receptor and that are suitable for use in pharmaceutical compositions. The present invention also provides methods of treatment using the mimetics of erythropoietin as well as methods of making the mimetics of erythropoietin.
    Type: Application
    Filed: May 11, 2012
    Publication date: February 5, 2015
    Inventors: Hendrik Mario Geysen, Cyrille V. Gineste
  • Patent number: 8946150
    Abstract: The present invention relates to novel polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W, where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. The present invention relates a composition containing the novel polypeptides, and use of same in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: February 3, 2015
    Assignee: Medical Diagnostic Laboratories, LLC.
    Inventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
  • Patent number: 8946146
    Abstract: The present invention provides a method of modulating appetite and/or body weight in a subject, said method comprising administering to said subject an effective amount of a MIC-1-modulating agent, wherein said agent increases or decreases the amount of MIC-1 present in said subject, or inhibits or enhances the biological activity of MIC-1 present in said subject.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: February 3, 2015
    Assignee: St Vincent's Hospital Sydney Limited
    Inventors: Samuel Norbert Breit, Asne Rhoda Bauskin
  • Publication number: 20150030688
    Abstract: Tissue engineering structures with biologically favorable structural and chemical properties are disclosed. More particularly, the present disclosure is directed to tissue engineered scaffolds having a fiber support and honey. The tissue engineered scaffolds having a fiber support and honey can further include at least one biomolecule. The tissue engineered scaffolds can be used to promote cellular chemotaxis, enhance cell proliferation, enhance extracellular matrix production, increase angiogenesis, and provide antimicrobial activity. The nature of the tissue engineered scaffolds provides a template for cellular infiltration and guide tissue regeneration. The tissue engineered scaffolds can be used in the treatment of dermal wounds (burns, chronic wounds, etc.) or as a tissue engineering scaffold in a wide range of applications.
    Type: Application
    Filed: July 22, 2014
    Publication date: January 29, 2015
    Inventors: Scott Allen Sell, Benjamin Alexander Minden-Birkenmaier
  • Patent number: 8936804
    Abstract: This invention provides a method of promoting bone healing by locally administering a vanadium-based insulin mimetic agent to a patient in need thereof. The invention also provides a new use of insulin-mimetic vanadium compounds for manufacture of medicaments for accelerating bone-healing processes. In addition, the invention also encompasses a bone injury treatment kit suitable for localized administration of insulin-mimetic vanadium compounds or compositions thereof to a patient in need of such treatment.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: January 20, 2015
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Sheldon Suton Lin, David Naisby Paglia, James Patrick O'Connor, Eric Breitbart, Joseph Benevenia
  • Publication number: 20150018750
    Abstract: As the percentage of senior citizens increases at the present time, the purpose of the present invention is to provide a cosmetic which can maintain the skin in a healthy state by preventing damage to the skin that accompanies aging, more specifically, discoloration and wrinkling, is very safe, does not pose ethical problems, and can be supplied in a sufficient amount. The present invention provides a cosmetic that comprises as the main component a powder of the supernatant produced by culturing the bone marrow or dental pulp stem cells of a nonhuman mammal. Moreover, provided is a method for ion introduction for protein by which the cosmetic is introduced by ion introduction.
    Type: Application
    Filed: August 8, 2014
    Publication date: January 15, 2015
    Inventors: Minoru Ueda, Yasuhiro Yamashita
  • Publication number: 20150018273
    Abstract: The present invention provides a composition for stimulating hair growth in a mammal comprising a modified osteopontin polypeptide in which an RGD domain is inactivated; and a pharmaceutically acceptable and/or cosmetically acceptable excipient, carrier or diluent. The invention further provides methods of stimulating hair growth in a mammal.
    Type: Application
    Filed: August 10, 2012
    Publication date: January 15, 2015
    Applicant: FOLICUM AB
    Inventors: Jan Alenfall, Pontus Duner, Anna Hultgardh Nilsson
  • Patent number: 8927022
    Abstract: The disclosure provides granular forms of porous biomaterials and methods for forming and applying these biomaterials, including uses to promote vascularization and tissue ingrowth.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: January 6, 2015
    Assignee: Healionics Corporation
    Inventors: Max Maginness, Andrew Marshall, Christine L. Glaister, Michel Alvarez
  • Publication number: 20150004131
    Abstract: A radiation protection device for providing protection of a body part that includes active bone marrow from ionizing radiation may include a radiation protection component configured to be placed adjacent to and externally cover the body part so as to reduce a radiation dose absorbed in that body part.
    Type: Application
    Filed: November 14, 2012
    Publication date: January 1, 2015
    Inventors: Oren MILSTEIN, Daniel LEVITT, Yoav TIKOCHINSKY, Eyal ZUR, Eran ZUR